Comparing SR 103 → SR 105 — TARDIVE DYSKINESIA AWARE WEEK

Struck = only in SR 103 · added = only in SR 105.

Previous
Latest
Bill Text - SR-103 skip to content home accessibility FAQ feedback sitemap login x Quick Search:
*LRB10410584LAW20660r* SR0105 LRB104 10584 LAW 20660 r SENATE RESOLUTION WHEREAS, Serious mental illnesses like bipolar disorder, major depressive disorder, and schizophrenia often require treatment with antipsychotic medications for effective management, and antipsychotic prescribing rates continue to rise;
Bill Number Bill Keyword Home Bill Information California Law Publications Other Resources My Subscriptions My Favorites Bill Information >> Bill Search >> Text Bill Text PDF2 Bill PDF |Add To My Favorites |Track Bill | Version:
and WHEREAS, While prolonged antipsychotic use may be essential for the treatment of certain conditions, it is associated with tardive dyskinesia (TD), a condition marked by uncontrollable, abnormal, and repetitive movements of the face, torso, limbs, or extremities;
05/05/26 - Enrolled 04/27/26 - Introduced SR-103 (2025-2026) Text >> Votes >> History >> Bill Analysis >> Today's Law As Amended >> Compare Versions >> Status >> Comments To Author >> Track Bill >> Add To My Favorites >> SHARE THIS:
and WHEREAS, People at higher risk of TD include those older than 55 years, people who are Black, women, individuals with mood or substance use disorders, intellectual disabilities, or central nervous system injuries, and those with high cumulative antipsychotic exposure;
SR103:v98#DOCUMENTBill Start Enrolled  May 05, 2026 Passed  IN  Senate  May 04, 2026 CALIFORNIA LEGISLATURE— 2025–2026 REGULAR SESSION Senate Resolution No.
and WHEREAS, Approximately 60% of the estimated 800,000 U.S.
103Introduced by Senator Blakespear(Coauthors:
adults living with TD remain undiagnosed, and even mild TD symptoms can be stigmatizing and impair physical, social, and emotional well-being, underscoring the urgency of early screening, detection, and intervention;
Senators Alvarado-Gil, Archuleta, Jones, Laird, Niello, and Umberg)April 27, 2026 Relative to Tardive Dyskinesia Awareness Week.LEGISLATIVE COUNSEL'S DIGESTSR 103, Blakespear.
and SR0105 -2- LRB104 10584 LAW 20660 r WHEREAS, The American Psychiatric Association recommends routine TD screening in their clinical guidelines for antipsychotic treatment, and individuals treated with antipsychotics or experiencing abnormal movements should consult their health care providers to assess TD risk, receive TD screenings, and determine appropriate treatment together;
Digest KeyBill TextWHEREAS, Serious mental illnesses like bipolar disorder, major depressive disorder, and schizophrenia often require treatment with antipsychotic medications for effective management, and antipsychotic prescribing rates continue to rise;
and WHEREAS, FDA-approved treatments for TD can provide options for symptom management and improved quality of life for many individuals living with TD;
andWHEREAS, While prolonged antipsychotic use may be essential for the treatment of certain conditions, it is associated with tardive dyskinesia (TD), a condition marked by uncontrollable, abnormal, and repetitive movements of the face, torso, limbs, or extremities;
and WHEREAS, The General Assembly can encourage TD screening education and awareness for health care providers, patients, and care partners to help ensure patients prescribed antipsychotics receive care and support that aligns with clinical best practices, including regular TD screenings;
andWHEREAS, People at higher risk of TD include those 55 years of age or older, Black individuals, women, individuals with mood or substance use disorders, intellectual disabilities, or central nervous system injuries, and those with high cumulative antipsychotic exposure;
therefore, be it RESOLVED, BY THE SENATE OF THE ONE HUNDRED FOURTH GENERAL ASSEMBLY OF THE STATE OF ILLINOIS, that we declare May 4 through May 10, 2025 as Tardive Dyskinesia Awareness Week (TDAW) in the State of Illinois;
andWHEREAS, Approximately 60 percent of the estimated 800,000 adults in the United States living with TD remain undiagnosed, and even mild TD symptoms can be stigmatizing and impair physical, social, and emotional well-being, underscoring the urgency of early screening, detection, and intervention;
and be it further RESOLVED, That we support TDAW in recognition of the importance of early detection and intervention to improve SR0105 -3- LRB104 10584 LAW 20660 r outcomes for people living with mental health conditions and prescribed antipsychotics, and we support efforts to raise awareness about the causes and symptoms of tardive dyskinesia (TD) and the importance of routine TD screening.
andWHEREAS, The American Psychiatric Association recommends routine TD screening in their clinical guidelines for antipsychotic treatment, and individuals treated with antipsychotics or experiencing abnormal movements should consult their health care providers to assess TD risk, receive TD screenings, and determine appropriate treatment together;
andWHEREAS, Treatments approved by the United States Food and Drug Administration for TD can provide options for symptom management and improved quality of life for many individuals living with TD;
andWHEREAS, California can encourage TD screening education and awareness for health care providers, patients, and care partners to help ensure patients prescribed antipsychotics receive care and support that aligns with clinical best practices, including regular TD screenings;
now, therefore, be itResolved by the Senate of the State of California, That the Senate proclaims the first full week in May 2026 as “Tardive Dyskinesia Awareness Week” (TDAW), and, in recognition and support of TDAW, underscores the importance of early detection and intervention to improve outcomes for people living with mental health conditions and prescribed antipsychotics and supports efforts to raise awareness about the causes and symptoms of TD and the importance of routine TD screening;
and be it furtherResolved, That the Secretary of the Senate transmit copies of this resolution to the author for appropriate distribution.